Precision medicine against cancer: create the most appropriate treatments for each patient with AI

KeyZell develops novel oncology drugs and finds the most efficient combination of treatments according to each genetics and clinical history.

Covid-19 placed the importance of scientific research at the forefront of public opinion . After two years of the pandemic, and in a situation of greater stability thanks to vaccination, researchers raise their voices so that the effort does not falter in other diseases where the battle has not yet been won .

“Research into the cure of cancer stopped with the pandemic and some researchers, led by the facilities of resources and approvals, decided to abandon the investigation of another true pandemic, cancer . It would be surprising to see the mortality data for people not treated or diagnoses cancer patients. We don’t take the easy road, that says a lot about the people in the team”.

This is José del Corral, CEO of the biotech startup KeyZell , one of the leading players in the development of precision medicine in oncology.

“It is a key moment for scientific research, since, after two years of the pandemic in which all efforts have focused on covid, trials and research in other areas are being reactivated ,” he explains to D+ YO.

KeyZell is a Spanish biotechnological startup located in Seville that focuses on the research and development of a new generation of anticancer drugs and an innovative oncology precision medicine system based on artificial intelligence.

Human team that makes up the KeyZell biotechnology company.

“We started as an altruistic project more than three years ago  among several professionals, who have also been friends for a long time, and we established ourselves as a company in 2020. We have collaborators all over the world and we have an operating subsidiary in Australia,” says José del Corral.

KeyZell is currently working on several first-line treatments against some of the main types of oncological tumors and is awaiting the start of phase I/IIa clinical trials. in Australia and Mexico.

In addition, one of its strong points in terms of technology is its innovative artificial intelligence system that aspires to guide the future of precision medicine in oncology. The startup is capable of associating genetic and epigenetic patterns with the available treatments to obtain the most suitable one for each patient.

“When a person is diagnosed with cancer, they usually receive the same treatment as other people who have the same type and stage as their cancer. However, each patient is different and can respond totally differently to treatments . An example is the limitation of use due to allergy to a certain medication”, argues the CEO.

José del Corral, CEO of KeyZell.

“Our OPS artificial intelligence system will be able, based on a large amount of input data, such as genomic information, clinical history and approved treatments, to recognize patterns that allow it to find the most efficient combination of drugs for each patient . “.

The project is very advanced, in fact, it is the prelude to starting the clinical trial in humans after having achieved a total cure in animals.

“Being on the verge of starting a clinical trial in humans is already a milestone. When we talk about drug research, the development process is long and costly since it has to demonstrate, throughout its different phases, that the drug meets all the regulated requirements. Only 1 in 10,000 molecules reaches the final phase in humans , and that is where KeyZell is,” says the head of the biotechnology company.

“Furthermore, it was extremely exciting when Dr. Hajji shared with us the news that during the investigation they had achieved a total cure in animals “, adds Del Corral.

Dr. Nabil Hajji, Principal Investigator at KeyZell Biotech.

Dr. Hajji is, precisely, one of the pillars of Spanish biotechnology , the main researcher at KeyZell, without whose research the company would not have reached the advanced stage in which its scientific project is today.

The company has just opened a new round of private investment to finance the next clinical trials in Australia and Mexico and continue the training of the OPS Artificial Intelligence system.

“We are sure that we will be able to close it successfully within the foreseen period, given the interest that KeyZell has aroused among some of the most representative international investment funds “, clarifies the CEO.

“In addition, we are working in different countries to close agreements that allow us to start trials of our drug in patients and its subsequent marketing,” he concludes.

His impact project thus becomes one of the world’s leading names in the fight against cancer and an example of the enormous potential that the technology-scientific research binomial has to offer hope to millions of people all over the planet.

See here the complete article of El Español.

Dr Nabil Hajji

Dr Nabil Hajji

World-renowned expert in the field of oncology, recognized for establishing the mechanism underlying the resistance of classical antitumor treatments in various types of cancer, related to the epigenetic mechanism that controls apoptosis and the tumor microenvironment.

Dr Nabil Hajji

Dr Nabil Hajji

World-renowned expert in the field of oncology, recognized for establishing the mechanism underlying the resistance of classical antitumor treatments in various types of cancer, related to the epigenetic mechanism that controls apoptosis and the tumor microenvironment.

Recent news

Follow us on the networks

Subscribe to our newsletters

You will only receive notifications about new news and updates.

More news

Premios EmprendeXXI de CaixaBank

KeyZell finalist in CaixaBank’s Emprende XXI Awards

KeyZell, a company dedicated to the development of artificial intelligence technology applied to cancer, has been selected as a finalist in the EmprendeXXI Awards. These ...
Read more →

KeyZell participates as a reference in biotechnology in the new edition of MAD e-Health

KeyZell has been one of the companies invited to participate on April 28th in the Madrid Capital e-Health cluster (link). The event aims to bring ...
Read more →

KeyZell awarded with the Andalucía Excelente prize, best Biotechnology company 2022.

KeyZell received the Andalucía Excelente Award as the best Biotechnology company 2022. KeyZell, awarded for its commitment to create a new future for oncology, through ...
Read more →

Comitas e-health and Keyzell implement an AI solution for the early detection of lung and breast cancer

Comitas e-health and the Andalusian company Keyzell have formalized an alliance for the development of an innovative telemedicine solution for the early diagnosis and treatment ...
Read more →

KeyZell develops the first precision medicine system to fight breast and lung cancer

The startup has developed the first oncology precision medicine system that selects “personalized treatment for each patient.”- Seguir leyendo:   As explained by the company ...
Read more →

Fourier Intelligence, iRhythm and KeyZell are the most internationally recognized companies for revolutionizing the health sector

Health Tech World has released a compilation of the top 50 health technology innovators of 2022 who stand out for their unique innovation, outstanding technology ...
Read more →

KeyZell has been awarded as the “Most Pioneering Biotechnology Company – Europe”

KeyZell has been awarded as the “Most Pioneering Biotechnology Company – Europe” in the seventh edition of the “International Life Sciences Awards 2022“. This event ...
Read more →

KeyZell continues to advance in the development of its Artificial Intelligence tool

The biotech startup KeyZell has officially announced the launch of its exclusive fungible token useful to receive the service of its Artificial Intelligence system for precision medicine ...
Read more →

Revealed: The Health Tech World Top 50 Innovators of 2022

Health Tech World has announced its Top 50 health tech innovators of 2022. Here are the top picks of health tech companies who stand out ...
Read more →